TUESDAY, Jan. 31 (HealthDay News) -- A new Swiss-American study
indicates that long-term use of the popular diabetes medication
metformin may lower the risk of developing pancreatic cancer, at
least among women.
The researchers also found that the long-term use of another
class of diabetes medications known as sulfonylureas was associated
with a "substantial" bump in pancreatic risk and long-term insulin
use was linked to a bump in pancreatic cancer risk in men.
"This result is somewhat unexpected," the team wrote in its paper, which is published in the Jan. 31 online issue of The American Journal of Gastroenterology.
Pancreatic cancer is the fourth most deadly cancer in the United
States, with an overall survival rate of less than 5 percent, even
though it is fairly rare, according to the U.S. National Institutes
The researchers noted that previous research has suggested that
metformin may lower the risk for other cancers, breast and ovarian
cancer in particular.
To explore metformin's protective potential against pancreatic
cancer, the team sifted through drug prescription, diagnostic,
hospitalization and fatality information that had been collected by
the British "General Practice Research Database." The data also
included significant demographic information, such as smoking,
alcohol use and body mass index.
The team honed in on statistics regarding nearly 2,800 patients
(all under the age of 90) who had been diagnosed with pancreatic
cancer for the first time between 1995 and 2009. Data concerning
almost 16,600 patients who did not have pancreatic cancer was used
as a comparison.
The result: Short-term use of metformin or sulfonylureas and/or
insulin had no appreciable impact on pancreatic cancer risk.
long-term use of each of these medications did appear to have
a sizeable impact on pancreatic cancer risk among diabetics. While
female patients saw their risk go down with metformin treatment and
up with sulfonylureas, male patients saw their risk go up with
Dr. Michael Choti, a professor of surgery and oncology at the
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University in Baltimore, stressed the "importance of trying to
identify causes for a devastating disease that is often diagnosed
"Over the years, many groups have tried to look at a variety of risk factors, dietary and other things, and there have been some reports over the years," he noted. "But nothing has really panned out well. So this is indeed an interesting study."
"But it's also important to say," Choti added, "that while these could be associations, we cannot really say that what we have here is a cause-and-effect. Pancreatic cancer is a multi-factorial disease. So, while it makes sense conceptually that these drugs could have an impact on the pancreas, which is a metabolic organ, it's still too early to be sure what's happening. And it's too early to recommend metformin as a preventive therapy for pancreatic cancer."
"So this is interesting and important," he said. "But it's not definitive."
For more on pancreatic cancer, visit the
U.S. National Library of Medicine.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.